fhB7H3.CAR-Ts
Phase 2Cell therapy
fhB7H3.CAR-Ts is one of 96 biologic programs targeting Liver Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
232 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Hycamtin
MMeitheal
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Femara
NovartisPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Adriamycin
PfizerPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Trodelvy
GileadPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Afinitor
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for fhB7H3.CAR-Ts. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details